Skip to content

ArriVent BioPharma, Inc. AVBP Market capitalization

Market capitalization at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$588.76B+47.3%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$2.06B+95.0%
Nuvation Bio logo
Nuvation BioNUVB
$1.49B+150%
Immunome logo
ImmunomeIMNM
$2.47B+323%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2.71B+226%
Erasca, Inc. logo
Erasca, Inc.ERAS
$5.03B+1,196%

Other financials

Income statement

See full
Operating income-$46.1M+30.9%
Net income-$43.3M+32.7%
EPS (diluted)-$0.96+49.5%

Balance sheet

See full
Cash & equivalents$62.1M+24.5%
Total debt$419.0K+204%
Total equity$324.0M+60.0%
Total assets$349.3M+62.1%

Cash flow

See full
Operating cash flow-$41.9M+38.4%

Valuation

See full
Enterprise value$1.51B+65.4%

Returns & leverage

See full
Return on equity-55.2%+8.0pp
Debt / equity0.0×
Current ratio14×-0.4×

Where this comes from

Computed from the period-end share price: $1.02B.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s market capitalization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s market capitalization?
ArriVent BioPharma, Inc. (AVBP) reported market capitalization of $1.02B in Q1 2026.
How has ArriVent BioPharma, Inc.'s market capitalization changed year-over-year?
ArriVent BioPharma, Inc.'s market capitalization increased by 62.1% year-over-year, from $628.96M to $1.02B.
What does market capitalization mean?
The total market value of the company's equity at the quarter end (share price × shares outstanding), sampled from daily market data. The latest point tracks the live price.